Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin

European Journal of Heart Failure

Volumn 12, Issue 4, 2010, Pages 354-359

  Calvin, Andrew D ^a   Somers, Virend K ^b   Steensma, David P ^b   Rio Perez, Jose A ^c   Van Der Walt, Christelle ^b   Fitz Gibbon, Jennifer M ^b   Scott, Christopher G ^b   Olson, Lyle J ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

Erythropoietin; Heart failure; Hypoxaemia; Sleep apnoea

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CENTRAL SLEEP APNEA SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOXEMIA; MALE; NOCTURNAL HYPOXEMIA; OXYGEN SATURATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

AGED; ANOXIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ERYTHROPOIETIN; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXYGEN CONSUMPTION; POLYSOMNOGRAPHY; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, CENTRAL; STATISTICS AS TOPIC;

EID: 77950252175     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq005     Document Type: Article

References (30)

1. Bradley TD, Floras JS. Sleep apnea and heart failure: part II: central sleep apnea. Circulation 2003;107:1822-1826.
2. Javaheri S, Parker TJ, Liming JD, Corbette WS, Nishiyama H, Wexler L, Roselle GA. Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation 1998;97:2154-2159.
3. Sin DD, Logan AG, Fitzgerald FS, Liu PO, Bradley TD. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000;102:61-66.
4. Lanfranchi PA, Braghiroli A, Bosimini E, Mazzuero G, Colombo RMS, Donner CF, Giannuzzi P. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;99:1435-1440.
5. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythro-poietin. Cardiovasc Res 2003;59:538-548.
6. Knaupp W, Khilnani S, Sherwood J, Scharf SM, Steinberg H. Erythropoietin response to acute normobaric hypoxia in humans. J Appl Physiol 1992;73: 837-840.
7. Winnicki M, Shamsuzzaman AS, Lanfranchi PA, Accurso V, Olson E, Davison D, Somers VK. Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004; 17:783-786.
8. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G. Circulating erythropoietin levels and prognosis in patients with congestive heart failure. Arch Intern Med 2005;165:1304-1309.
9. Volpe M, Tritto C, Testa U, Rao MAE, Martucci R, Mirante A, Enea I, Russo R, Rubattu S, Condorelli G, Cangianiello S, Trimarco B, Peschle C, Condorelli M. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994;74:468-473.
10. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.
11. Rui T, Feng Q, Lei M, Peng T, Zahang J, Xu M, Abel ED, Xenocostas A, Kvietys PR. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005;65:719-727.
12. van de Meer P, Lok DJ, Januzzi JL, de la Porte PWB-A, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, Van Veldhuisen DJ. Adequacy of endogenous erythro-poietin levels and mortality in anemic heart failure patients. Eur Heart J 2008;29: 1510-1515.
13. Naughton MT, Benard D, Liu PP, Rutherford R, Rankin F, Bradley TD. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1995;152:473-479.
14. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Iber C, Ancoli-Isreal S, Chesson A, Quan SF, American Academy of Sleep Medicine. The AASM Manual for the scoring of sleep and associated events: rules, terminology, and technical specifications. Westchester, IL:Medicine AAoS; 2007.
16. van de Meer P, Voors AA, Lipsic E, Smilde TDS, van Gilst WH, Van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004;44:63-67.
17. Arzt M, Floras JS, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanley PJ, Smilovitch M, Ryan CM, Tomlinson G, Bradley TD, CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure\a post hoc analysis of CANPAP. Circulation 2007;115:3173-3180.
18. Corra U, Pistono M, Mezzani A, Braghiroli A, Giordano A, Lanfranchi PA, Bosimini E, Gnemmi M, Giannuzzi P. Sleep and exertional periodic breathing in chronic heart failure. Circulation 2006;113:44-50.
19. Andreas S, Hagenah G, Moller C, Werner GS, Kreuzer H. Cheyne-Stokes respiration and prognosis in congestive heart failure. Am J Cardiol 1996;78:1260-1264.
20. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-571.
21. Naughton MT, Benard DC, Liu PP, Rutherford R, Rankin F, Bradley TD. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1995;152:473-479.
22. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metabol 2000;85:1151-1158.
23. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing in Collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). J Am Coll Cardiol 2008;52:686-717.
24. Albitar S, Genin R, Fen-Chong M, Serveaux M, Bourgeon B. High dose enalapril impairs the response to erthropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998;13:1206-1210.
25. Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 2003;23: 287-293.
26. Eckardt KU, Kurtz A, Bauer C. Regulation of erythropoietin production is related to proximal tubular function. Am J Physiol Renal Physiol 1989;256:F942-F947.
27. Quaschning T, Ruschitzka F, Stallmach T, Shaw S, Morawietz H, Goettsch W, Hermann M, Slowinski T, Theuring F, Hocher B, Luscher TF, Gassmann M. Erthropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J 2002;17:259-261.
28. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DB. Influence of recombinant human ery-thropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol Endocrinol Metabol 1991;261:642-646.
29. Rodrigue ME, Brochu I, D'orleans-Juste P, Larivierea R, Lebel M. Effect of erythro-poietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system. Am J Hypertens 2008;21:639-643.
30. Heidenreich S, Rahn K, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991;39:259-265.